Change of gene mutations and IGF1R expression during idelalisib treatment. (A) Number of somatic mutations at baseline and at time point of progressive disease in patients with available nontumor control. (B) Acquired or expanding mutations as total number (upper panel) or per year of idelalisib treatment (lower panel) per patient in dependence of response. (C) Variant allele frequency at baseline (BL) and at timepoint of PD for single mutations in selected genes. Percentages derive from WES (dark blue) or targeted NGS (light blue) only from patients/samples with tumor cell purity of >80%. (D) Variant allele frequency of MAKP/ERK pathway mutations over time. *MAP3K5 R591H is not detected at baseline. (E) Fold difference in IGF1R expression at time of progression compared with treatment initiation calculated using ΔΔCt method with 2 different primer pairs. Red arrows denote the primer positions in IGF1R gene.